as of 12-01-2025 4:00pm EST
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 141.8M | IPO Year: | 2010 |
| Target Price: | N/A | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $6.08 | Next Earning Date: | 11-06-2025 |
| Revenue: | $52,932,000 | Revenue Growth: | -17.87% |
| Revenue Growth (this year): | 12.88% | Revenue Growth (next year): | 21.64% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
10% Owner
Avg Cost/Share
$1.67
Shares
253,533
Total Value
$422,766.28
Owned After
179,989
10% Owner
Avg Cost/Share
$1.75
Shares
107,490
Total Value
$188,107.50
Owned After
179,989
10% Owner
Avg Cost/Share
$1.74
Shares
153,318
Total Value
$266,972.63
Owned After
179,989
Director
Avg Cost/Share
$1.56
Shares
8,952
Total Value
$13,988.40
Owned After
138,951
SEC Form 4
10% Owner
Avg Cost/Share
$1.95
Shares
1,082,459
Total Value
$2,101,031.57
Owned After
179,989
10% Owner
Avg Cost/Share
$1.80
Shares
548,211
Total Value
$986,450.87
Owned After
179,989
Director
Avg Cost/Share
$1.74
Shares
1,413
Total Value
$2,458.62
Owned After
87,416
SEC Form 4
10% Owner
Avg Cost/Share
$1.73
Shares
208,318
Total Value
$361,369.23
Owned After
179,989
10% Owner
Avg Cost/Share
$1.70
Shares
306,682
Total Value
$520,378.02
Owned After
179,989
Chief Financial Officer
Avg Cost/Share
$2.51
Shares
6,239
Total Value
$15,628.70
Owned After
70,636
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | CDXS | 10% Owner | Dec 1, 2025 | Sell | $1.67 | 253,533 | $422,766.28 | 179,989 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 28, 2025 | Sell | $1.75 | 107,490 | $188,107.50 | 179,989 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 26, 2025 | Sell | $1.74 | 153,318 | $266,972.63 | 179,989 | |
| WOLF DENNIS P | CDXS | Director | Nov 21, 2025 | Sell | $1.56 | 8,952 | $13,988.40 | 138,951 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 12, 2025 | Sell | $1.95 | 1,082,459 | $2,101,031.57 | 179,989 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 11, 2025 | Sell | $1.80 | 548,211 | $986,450.87 | 179,989 | |
| De Vre Raymond | CDXS | Director | Nov 11, 2025 | Sell | $1.74 | 1,413 | $2,458.62 | 87,416 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 10, 2025 | Sell | $1.73 | 208,318 | $361,369.23 | 179,989 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Nov 7, 2025 | Sell | $1.70 | 306,682 | $520,378.02 | 179,989 | |
| Erbez Georgia | CDXS | Chief Financial Officer | Oct 13, 2025 | Sell | $2.51 | 6,239 | $15,628.70 | 70,636 |
See how CDXS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CDXS Codexis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.